Gujarat Terce Laboratories Ltd. (BSE: 524314) is an Ahmedabad, Gujarat-based company in the Pharmaceuticals industry. With a market capitalisation of ₹34 Cr, it ranks #4,078 by market cap among the 6,197 Indian listed companies on FinBizNet, and #53 of 63 in Pharmaceuticals. At ₹43.00 (as of 16 Nov 2026), the share price is 14.0% below its 52-week high of ₹50.00 and 48.3% above its 52-week low of ₹29.00. The share price is down 0.3% over one year and up 18.8% over three months.
| Current Price | ₹43.00 |
|---|---|
| Market Cap | ₹34 Cr |
| BSE Code | 524314 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 14.7 |
| Return on Equity | 27.14% |
| Return on Assets | 8.77% |
| 52-Week Range | ₹29.00 – ₹50.00 |
| 1-Year Price Change | -0.3% |
| 3-Month Price Change | +18.8% |
| Beta (1Y) | 0 |
| Headquarters | Ahmedabad, Gujarat |
| Website | www.gujaratterce.in |
| Revenue | ₹9 Cr |
|---|---|
| Net Profit | ₹-0 Cr |
| Net Margin | -2.0% |
| EPS (Basic) | ₹0.23 |
| Basis | standalone |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Gujarat Terce Laboratories Ltd. reported revenue of ₹9 Cr in Q1 FY27, down 17.1% from ₹11 Cr in Q1 FY26 and down 21.1% from ₹11 Cr in Q4 FY26. It posted a net loss of ₹0 Cr for the quarter, against a net loss of ₹0 Cr in Q1 FY26. Across the 8 quarters from Q2 FY25 to Q1 FY27, quarterly revenue ranged from ₹9 Cr (Q1 FY27) to ₹13 Cr (Q2 FY25). The company reported a net loss in 3 of these 8 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q1 FY27 | ₹9 Cr | −₹0 Cr | −2.0% |
| Q4 FY26 | ₹11 Cr | ₹0 Cr | 0.9% |
| Q3 FY26 | ₹12 Cr | ₹1 Cr | 6.2% |
| Q2 FY26 | ₹13 Cr | ₹1 Cr | 10.8% |
| Q1 FY26 | ₹11 Cr | −₹0 Cr | −0.4% |
| Q4 FY25 | ₹12 Cr | −₹3 Cr | −27.5% |
| Q3 FY25 | ₹13 Cr | ₹1 Cr | 8.0% |
| Q2 FY25 | ₹13 Cr | ₹1 Cr | 11.1% |
Standalone figures (₹ crore, XBRL filings).
Promoters held 70.86% of Gujarat Terce Laboratories Ltd.'s shares as of Mar 2026, unchanged from Mar 2025. Delivery averaged 80.5% of traded volume across 15 BSE sessions (21 Oct 2026 – 13 Nov 2026).
Gujarat Terce Laboratories Limited develops, manufactures, markets, and distributes medicines and healthcare products in India and internationally. The company offers generic pharmaceutical for therapeutic areas, such as antibiotics, respiratory, nutraceuticals, gastrology, gynecology, pain therapy, and ayurvedic. It provides tablets, capsules, oral liquids, ointments, and injections under the Acolate, Tynol, Resplash, Ferlit, Z-Oxi, Vitfol, Thyter, Aziter, Codimol, Cefter, and Terflora brands. Gujarat Terce Laboratories Limited was incorporated in 1985 and is based in Ahmedabad, India.
1. Pharmaceutical-This segment manufactures and markets medical and pharmaceutical preparations. It offers branded and generic formulations covering various therapeutic areas, such as antibiotics, respiratory, nutraceuticals, gastrointestinal, anti-fungal, and others. 2. Metal-This segment manufactures copper sulphate. 3. Corporate-0 4. Segment Adjustment-0
1. Pharmaceutical-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Gujarat Terce Laboratories Ltd. | ₹34 Cr | 14.7 | 27.14% | ₹9 Cr | -0.3% |
Listed by market capitalisation. Ratios are shown for context only.
Gujarat Terce Laboratories Ltd. is trading at ₹43.00, with a market capitalisation of ₹34 Cr.
Gujarat Terce Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Gujarat Terce Laboratories Ltd. has a P/E of 14.7 and a return on equity of 27.14%.
Gujarat Terce Laboratories Ltd. is listed on the BSE under the scrip code 524314.
Gujarat Terce Laboratories Ltd.'s share price is down 0.3% over one year and up 18.8% over three months. Its 52-week range is ₹29.00 to ₹50.00.
In Q1 FY27, Gujarat Terce Laboratories Ltd. reported revenue of ₹9 Cr and net profit of ₹-0 Cr, with basic EPS of ₹0.23 (standalone, parsed from the company's exchange filing).
Gujarat Terce Laboratories Ltd. reported revenue of ₹9 Cr in Q1 FY27, down 17.1% from ₹11 Cr in Q1 FY26 and down 21.1% from ₹11 Cr in Q4 FY26.
Promoters held 70.86% of Gujarat Terce Laboratories Ltd.'s shares as of Mar 2026, unchanged from Mar 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.